A PDF of an earlier study of Doxorubicin/Docetaxel combo:
http://www.tumorionline.it/allegati/00445_2009_04/fulltext/02-Livi%20(422-426).pdf
An interesting pull from from the foreword:
"Anthracyclines such as doxorubicin play a central role in the management of advanced breast cancer. Treatment with anthracycline-containing regimens results in significant improvements in response rates and time to progression, compared with non-anthracycline regimens1-3, and approximately
20% of patients in whom a complete
response is achieved remain in remission after 10 years"